Kramer Anneke, Pippias Maria, Noordzij Marlies, Stel Vianda S, Afentakis Nikolaos, Ambühl Patrice M, Andrusev Anton M, Fuster Emma Arcos, Arribas Monzón Federico E, Åsberg Anders, Barbullushi Myftar, Bonthuis Marjolein, Caskey Fergus J, Castro de la Nuez Pablo, Cernevskis Harijs, des Grottes Jean-Marin, Garneata Liliana, Golan Eliezer, Hemmelder Marc H, Ioannou Kyriakos, Jarraya Faical, Kolesnyk Mykola, Komissarov Kirill, Lassalle Mathilde, Macario Fernando, Mahillo-Duran Beatriz, Martín de Francisco Angel L, Palsson Runolfur, Pechter Ülle, Resic Halima, Rutkowski Boleslaw, Santiuste de Pablos Carmen, Seyahi Nurhan, Simic Ogrizovic Sanja, Slon Roblero María F, Spustova Viera, Stojceva-Taneva Olivera, Traynor Jamie, Massy Ziad A, Jager Kitty J
ERA-EDTA Registry, Department of Medical Informatics, Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands.
Hellenic Renal Registry, Board of Registry, Coordination and Control of RRT, General Hospital of Athens 'G. Gennimatas', Athens, Greece.
Clin Kidney J. 2018 Feb;11(1):108-122. doi: 10.1093/ckj/sfx149. Epub 2018 Jan 5.
This article summarizes the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Registry's 2015 Annual Report. It describes the epidemiology of renal replacement therapy (RRT) for end-stage renal disease (ESRD) in 2015 within 36 countries.
In 2016 and 2017, the ERA-EDTA Registry received data on patients who were undergoing RRT for ESRD in 2015, from 52 national or regional renal registries. Thirty-two registries provided individual patient-level data and 20 provided aggregated-level data. The incidence, prevalence and survival probabilities of these patients were determined.
In 2015, 81 373 individuals commenced RRT for ESRD, equating to an overall unadjusted incidence rate of 119 per million population (pmp). The incidence ranged by 10-fold, from 24 pmp in Ukraine to 232 pmp in the Czech Republic. Of the patients commencing RRT, almost two-thirds were men, over half were aged ≥65 years and a quarter had diabetes mellitus as their primary renal diagnosis. Treatment modality at the start of RRT was haemodialysis for 85% of the patients, peritoneal dialysis for 11% and a kidney transplant for 4%. By Day 91 of commencing RRT, 82% of patients were receiving haemodialysis, 13% peritoneal dialysis and 5% had a kidney transplant. On 31 December 2015, 546 783 individuals were receiving RRT for ESRD, corresponding to an unadjusted prevalence of 801 pmp. This ranged throughout Europe by more than 10-fold, from 178 pmp in Ukraine to 1824 pmp in Portugal. In 2015, 21 056 kidney transplantations were performed, equating to an overall unadjusted transplant rate of 31 pmp. This varied from 2 pmp in Ukraine to 94 pmp in the Spanish region of Cantabria. For patients commencing RRT during 2006-10, the 5-year unadjusted patient survival probabilities on all RRT modalities combined was 50.0% (95% confidence interval 49.9-50.1).
本文总结了欧洲肾脏协会 - 欧洲透析与移植协会（ERA - EDTA）登记处的2015年度报告。它描述了2015年36个国家中终末期肾病（ESRD）的肾脏替代治疗（RRT）的流行病学情况。
2016年和2017年，ERA - EDTA登记处从52个国家或地区肾脏登记处接收了2015年接受ESRD的RRT患者的数据。32个登记处提供了个体患者层面的数据，20个提供了汇总层面的数据。确定了这些患者的发病率、患病率和生存概率。
2015年，81373人开始接受ESRD的RRT治疗，总体未调整发病率为每百万人口119例（pmp）。发病率相差10倍，从乌克兰的每百万人口24例到捷克共和国的每百万人口232例。开始接受RRT治疗的患者中，近三分之二为男性，超过一半年龄≥65岁，四分之一的主要肾脏诊断为糖尿病。RRT开始时的治疗方式为85%的患者接受血液透析，11%接受腹膜透析，4%接受肾移植。开始RRT治疗91天时，82%的患者接受血液透析，13%接受腹膜透析，5%接受肾移植。2015年12月31日，546783人接受ESRD的RRT治疗，未调整患病率为每百万人口801例。这在整个欧洲相差超过10倍，从乌克兰的每百万人口178例到葡萄牙的每百万人口1824例。2015年进行了21056例肾移植，总体未调整移植率为每百万人口31例。这从乌克兰的每百万人口2例到西班牙坎塔布里亚地区的每百万人口94例不等。对于2006 - 2010年开始接受RRT治疗的患者，所有RRT方式联合的5年未调整患者生存概率为50.0%（95%置信区间49.9 - 50.1）。
